Status:
COMPLETED
Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
Aerie Pharmaceuticals
Conditions:
Ocular Hypertension
Suspect Glaucoma
Eligibility:
All Genders
18-88 years
Brief Summary
Rhopressa effectively lowers intra-ocular pressure by improving conventional outflow and decreasing episcleral venous pressure. While this may result in improved episcleral venous flow, current method...
Detailed Description
Need/Relevance: Rhopressa effectively lowers intra-ocular pressure by improving conventional outflow and decreasing episcleral venous pressure. While this may result in improved episcleral venous flo...
Eligibility Criteria
Inclusion
- Patients at least 18 years of age.
- Patients must have ocular hypertension or be a glaucoma suspect.
- Patients must be treatment naïve without alternative study treatments or previous history of using topical IOP lowering agents.
- Patients must have an IOP of 24-30 mm Hg in the affected eye.
- Patients must have open angles on gonioscopy.
- Patients must be willing and able to comply with the protocol including providing informed consent.
- All patients will have at least one recorded visual field examination within 6 months of enrollment in the study. Visual fields will be assessed using the Hodapp-Andersen-Parish criteria.
Exclusion
- Prior intraocular surgery other than uncomplicated cataract surgery.
- Allergy or history of adverse reaction to ICG, shellfish, or Iodine.
- Significant liver disease or uremia.
- Secondary glaucoma including exfoliation glaucoma, pigmentary glaucoma, or history of acute angle closure.
- Greater than 6 diopters of refractive error.
- Moderate or severe visual field deficits as per Hodapp-Anderson-Parish criteria.
- Any condition precluding imaging including reliable visual fields, disc photography, or use of study treatments including media opacity or tilted optic disk.
- Pregnant or nursing patients.
Key Trial Info
Start Date :
March 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 22 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04401982
Start Date
March 15 2021
End Date
February 22 2022
Last Update
March 28 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201
2
University Physicians Inc.
Baltimore, Maryland, United States, 21201
3
UM Faculty Physicians, Inc. | 5900 Waterloo Crossing
Columbia, Maryland, United States, 21045
4
Maryland Eye Consultants and Surgeons
Silver Spring, Maryland, United States, 20902